<\/p>\n
Follow<\/span><\/span><\/span><\/button><\/div>\n\n<\/svg><\/span><\/span>Play Earnings Call<\/span><\/span><\/button><\/svg><\/span><\/span>Play Earnings Call<\/span><\/span><\/button><\/div>\n<\/div>\n\n\n\n\n\n\nMedinCell S.A. (MDCLF<\/span>) Q4 2026 Earnings Call June 16, 2026 12:00 PM EDT<\/p>\n<\/div>\n\nCompany Participants<\/strong><\/p>\nDavid Heuz\u00e9 – Head of Corporate & Financial Communications and ESG<\/span>Christophe Douat – CEO & Director<\/span>Stephane Postic – Chief Financial Officer<\/span><\/p>\n<\/p><\/div>\n\nConference Call Participants<\/strong><\/p>\nRaghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division<\/span>Shan Hama – Jefferies LLC, Research Division<\/span>Michael DiFiore – Evercore ISI Institutional Equities, Research Division<\/span>Marc Goodman – Leerink Partners LLC, Research Division<\/span>Nicolas Pauillac – Kepler Cheuvreux, Research Division<\/span><\/p>\n<\/p><\/div>\n\nPresentation<\/strong><\/p>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nHello, everyone. Thank you for joining MedinCell’s Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
MedinCell S.A. (MDCLF<\/span>) Q4 2026 Earnings Call June 16, 2026 12:00 PM EDT<\/p>\n<\/div>\n\nCompany Participants<\/strong><\/p>\nDavid Heuz\u00e9 – Head of Corporate & Financial Communications and ESG<\/span>Christophe Douat – CEO & Director<\/span>Stephane Postic – Chief Financial Officer<\/span><\/p>\n<\/p><\/div>\n\nConference Call Participants<\/strong><\/p>\nRaghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division<\/span>Shan Hama – Jefferies LLC, Research Division<\/span>Michael DiFiore – Evercore ISI Institutional Equities, Research Division<\/span>Marc Goodman – Leerink Partners LLC, Research Division<\/span>Nicolas Pauillac – Kepler Cheuvreux, Research Division<\/span><\/p>\n<\/p><\/div>\n\nPresentation<\/strong><\/p>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nHello, everyone. Thank you for joining MedinCell’s Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
Company Participants<\/strong><\/p>\nDavid Heuz\u00e9 – Head of Corporate & Financial Communications and ESG<\/span>Christophe Douat – CEO & Director<\/span>Stephane Postic – Chief Financial Officer<\/span><\/p>\n<\/p><\/div>\n\nConference Call Participants<\/strong><\/p>\nRaghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division<\/span>Shan Hama – Jefferies LLC, Research Division<\/span>Michael DiFiore – Evercore ISI Institutional Equities, Research Division<\/span>Marc Goodman – Leerink Partners LLC, Research Division<\/span>Nicolas Pauillac – Kepler Cheuvreux, Research Division<\/span><\/p>\n<\/p><\/div>\n\nPresentation<\/strong><\/p>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nHello, everyone. Thank you for joining MedinCell’s Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
David Heuz\u00e9 – Head of Corporate & Financial Communications and ESG<\/span>Christophe Douat – CEO & Director<\/span>Stephane Postic – Chief Financial Officer<\/span><\/p>\n<\/p><\/div>\n\nConference Call Participants<\/strong><\/p>\nRaghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division<\/span>Shan Hama – Jefferies LLC, Research Division<\/span>Michael DiFiore – Evercore ISI Institutional Equities, Research Division<\/span>Marc Goodman – Leerink Partners LLC, Research Division<\/span>Nicolas Pauillac – Kepler Cheuvreux, Research Division<\/span><\/p>\n<\/p><\/div>\n\nPresentation<\/strong><\/p>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nHello, everyone. Thank you for joining MedinCell’s Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
Conference Call Participants<\/strong><\/p>\nRaghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division<\/span>Shan Hama – Jefferies LLC, Research Division<\/span>Michael DiFiore – Evercore ISI Institutional Equities, Research Division<\/span>Marc Goodman – Leerink Partners LLC, Research Division<\/span>Nicolas Pauillac – Kepler Cheuvreux, Research Division<\/span><\/p>\n<\/p><\/div>\n\nPresentation<\/strong><\/p>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nHello, everyone. Thank you for joining MedinCell’s Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
Raghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division<\/span>Shan Hama – Jefferies LLC, Research Division<\/span>Michael DiFiore – Evercore ISI Institutional Equities, Research Division<\/span>Marc Goodman – Leerink Partners LLC, Research Division<\/span>Nicolas Pauillac – Kepler Cheuvreux, Research Division<\/span><\/p>\n<\/p><\/div>\n\nPresentation<\/strong><\/p>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nHello, everyone. Thank you for joining MedinCell’s Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
Presentation<\/strong><\/p>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nHello, everyone. Thank you for joining MedinCell’s Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
David Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nHello, everyone. Thank you for joining MedinCell’s Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
Hello, everyone. Thank you for joining MedinCell’s Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.<\/p>\n<\/p><\/div>\n
Christophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
Hello, everyone.<\/p>\n<\/p><\/div>\n
David Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n\nStephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
And Stephane Postic, our CFO. Hi, Stephane.<\/p>\n<\/p><\/div>\n
Stephane Postic<\/strong><\/span>Chief Financial Officer<\/i><\/span><\/p>\nHello, everyone.<\/p>\n<\/p><\/div>\n\nDavid Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
David Heuz\u00e9<\/strong><\/span>Head of Corporate & Financial Communications and ESG<\/i><\/span><\/p>\nAnd with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n\nChristophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
And with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?<\/p>\n<\/p><\/div>\n
Christophe Douat<\/strong><\/span>CEO & Director<\/i><\/span><\/p>\nThank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\nWhat is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
Thank you, David. Let me start with MedinCell’s trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell’s innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform. <\/p>\n
What is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
![\"\"](\"https:\/\/seekingalpha.com\/images\/users_profile\/000\/101\/639\/big_pic.png?io=w72)